RE: Tox Studies25 May 2026 10:10
I'm not sure the completion of dosing warrants an RNS although I hope they do release one. I guess, they will consult with the NOMAD to see what can and can't be said. Id be happy with a Chairman's corner. In terms of the study. Dosing complete, is only a small part of the story. Even when fully completed with a data readout. The whole study is just regulatory tick box that enables the next human phase.
However. If the dosing completes successfully, think we should start to see some buying pressure, especially if the peer reviewed data is published and shows that the bio markers were similar if not better to the Nimbus compound at the same stage.
While I hope negotiations are already underway, there should not be any exclusivity until there is actual cash on the table. I still believe we will be waiting until Q4, but if dosing completes without any issues, a significant portion of the risk will be eliminated.